InsidersTradesSigma
Total declarations
Companies
▲ Purchases (4 ops.)
▼ Sales (2 ops.)
Insider track record
OtherDisclosed buys
4
Disclosed sells
2
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Explore the detailed record of transactions filed by Gall Matthew. Director active across 2 companies, notably iTeos Therapeutics, Inc.. Aggregated, 10 filings have been recorded. Breakdown: 4 buys · 2 sells. Total volume traded: €704k. Activity tracked since 16 June 2021. The latest transaction was disclosed on 7 March 2025 (Attribution). Regulator: SEC (Form 4). The full history is openly available.
Declarations10 total
24,000 shares0Common StockSEC:0000950170-25-037512:0
5,000 shares@ US$7.7274.3% of flowCommon StockSEC:0000950170-24-128956:0
Ideal exit: 16 Aug 2025 (T+270)
41,000 shares0Common StockSEC:0000950170-23-068901:0
5,000 shares@ US$8.374.6% of flowCommon StockSEC:0001209191-23-052709:0
Ideal exit: 8 Jul 2024 (T+270)
5,000 shares@ US$46.4523.9% of flowCommon StockSEC:0001209191-21-071435
5,000 shares@ US$46.4526.2% of flowCommon StockSEC:0001209191-21-071435:0
14,429 shares@ US$6.169.8% of flowCommon StockSEC:0001209191-21-060297:0
14,429 shares@ US$6.169.0% of flowCommon StockSEC:0001209191-21-060297
5,000 shares@ US$26.089313.9% of flowCommon StockSEC:0000899243-21-024236:0
Ideal exit: 13 Mar 2022 (T+270)
5,000 shares@ US$26.089312.7% of flowCommon StockSEC:0000899243-21-024236
Ideal exit: 13 Mar 2022 (T+270)
10 of 10 declarations
About Gall Matthew
Matthew Gall is a director at iTeos Therapeutics, Inc.
